Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pluristem's GMP Facility Gains EU Approval | Contract Pharma
Breaking News

Pluristem’s GMP Facility Gains EU Approval

To use PLX cell therapies in Phase I-III trials

Pluristem Therapeutics’ new manufacturing facility has been approved by European auditors and has received the Qualified Person Declaration. The approval allows the company to use cell therapies manufactured at its facility in Haifa, Israel, in Phase I-III trials conducted in the EU.
 
The audit for manufacturing and cell expansion operations covered design, construction, and validation of the new facility, equipment, utilities, and quality management systems in accordance with GMP legislation, directives and guidelines.  
 
The facility houses the company’s fully automated 3D cell expansion manufacturing platform that uses high-throughput culturing technologies, 3D bioreactors, and downstream equipment, with the ability to produce approximately 150,000 doses of PLX cells annually.
 
“This Qualified Person declaration enables us to expand our clinical site locations into any European Union member nation through each phase of our trials,” stated Zami Aberman, chairman and chief executive officer of Pluristem. “We believe Pluristem’s advanced, commercial scale cell manufacturing facility is one of our Company’s key strategic assets and gives us significant competitive advantage in the industry as we move our clinical development pipeline forward.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters